clinical trial · NCT05726032
Empagliflozin in Patients With Cirrhosis and Ascites
Yale University·phase2·recruiting·n = 20
CirrhosisLiver FailureEmpagliflozin 10 MGMatching Placebo
brief summary
A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.
started
Sep 11, 2023
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Aug 21, 2026
official title
Effects of Empagliflozin on Natriuresis and Volume Overload in Patients With Cirrhosis and Ascites
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol